echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > "Magic new drug" promises to treat a variety of diseases: cancer, pain, depression

    "Magic new drug" promises to treat a variety of diseases: cancer, pain, depression

    • Last Update: 2020-07-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Opioid sadvances are a class of small molecular proteins that interact with four opioid receptors on the surface of central nervous system cells, functioning as neuromodulators and playa-in the process of pain relief and regulation of moods such as euphoria, anxiety, stress and depressionClass 4 opioid receptors include classic receptors mu (s or MOR), delta (sororor or DOR), kappa (sororor or KOR), and non-classical pain-sensitive peptide receptors (NOP, also known as the sophorine FQ receptor)severe pain is treated at this stage mainly by drug action on the opioid peptide systemAnalgesic prescription drugs, including morphine, oxycodone and fentanyl, can cause analgesic effects by targeting and activating opioid receptors, preventing the spread of "pain information" and altering pain sensebut the use of these painkillers often has side effects such as drug tolerance, drug dependence, and respiratory diseasesEspecially in the current "opioid crisis" is not optimistic, there is an urgent need for new opioid peptide system regulation methods, the use of a number of novel mechanisms and can reduce complications of drugs to play a role, researchers at the Luxembourg Institute of Health (LIH) Department of Infection and Immunology recently developed a new compound, LIH383, which binds and blocks the brain's new opioid receptor, ACKR3, to regulate levels of opioid-producing in the central nervous system and enhance the natural pain and antidepressant properties of opioid peptidesThe findings, published June 19 in Nature Communications, are important for developing new drugs to treat pain, depression and brain cancerPhoto Source: Nature Communicationsresearch team has demonstrated in previous studies that ACKR3 is a new type of opioid receptor with negative regulatory properties, and that ACKR3 is highly affinity for a variety of opioids in the brain morphorins, pain-sensitive and strong morphins familyHowever, when opioids bind to classic opioid receptors, they produce "information" that relieves pain or pacifying, but binding to ACKR3 does not produce this information" ACKR3 is an atypical opioid receptor that captures the secreted opioid peptides and reduces their level of interaction with traditional receptors, thereby reducing the effects of opioid peptides and acting as a negative regulator of the opioid peptide systemMax Meyrath, the paper's first author, explainsthe specific activation of opioids to ACKR3 (Photo: Nature Communications)researchers note that the detection of ACKR3 function has led to a new fine-tuning mechanism for the opioid peptide system, which regulates the abundance of natural opioid peptides by manipulating the fifth member of the opioid receptor familyBased on this mechanism, the researchers envisioned a new molecule that could enhance the natural beneficial effects of opioids on pain and negative emotions by targeting and blocking ACKR3, and LIH383 emergedSubsequently, the research team demonstrated the efficacy of LIH383 to regulate ACKR3 activity and filed a patent application in April 2020 the activity of opioid regulators and the development of LIH383 as ACKR3 selective agonists (Photo source: Nature Communications) in addition to being an opioid receptor, ACKR3 was initially called a chemofactor receptor because of its ability to bind to chemochemical factors, which are small molecular proteins secreted by immune cells, which mediate immune responses and also confirm the involvement of chemochemicals in tumor occurrence and metastasis specifically, ACKR3 is widely expressed in tumors such as glioblastoma and breast cancer, and the presence of ACKR3 is associated with tumor growth, metastasis, resistance to chemotherapy, and poor prognosis "LIH383 interacts with and interferes with ACKR3, so this finding is also expected to be used to treat metastatic cancer," said the paper's author, Dr Andy Chevign? related paper: max Meyrath et al The atypical chemokine e oer ACKR3/CXCR7 is a broad-spectrum scavenger for opioids Nature Communications (2020) References: 1 s Renewed Hope for Treatment of pain and depression (Source: Medical Press)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.